Shamburg News · 8-K filed Nov 12, 2026, 5:11 PM EST

Longeveron Reports Q3 2026 Results, Requests FDA Meeting and Starts Strategic Review

LGVN · Longeveron Inc.

  • Earnings
  • Other event
  • Materiality: high

Longeveron Inc. reported financial results for the three and nine months ended September 30, 2026, with a net loss of $6.1 million for the third quarter compared with $7.2 million a year earlier. Third-quarter revenue was $115 thousand and cash and cash equivalents were $7.2 million as of September 30, 2026. The company said it requested an FDA meeting after the ELPIS II trial did not meet its primary endpoint, and retained Lucid Capital Markets to explore strategic alternatives.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001213900-26-119052.

Written from the filing by Shamburg Markets. Figures are as reported by the company.